Literature DB >> 17899425

Pyrexia of unknown origin (PUO) in a hemodialysis patient.

Ananthakrishnapuram N Aravindan1, John Saunders, Bruce Cleland, Tim Spicer, Ken Howlin, Jeff Wong, Andrew Jefferys, Josephine Chow, Christopher Henderson, Michael Suranyi.   

Abstract

Patients with end stage renal disease (ESRD) are predisposed to malignancy. A patient who presented with a persisting fever, episodically above 38 degrees C, of unknown origin is described. The diagnosis of the illness remained elusive, over repeated hospital admissions and comprehensive investigations for over 11 weeks, until her last admission when the patient finally represented with features of acute liver cell failure and succumbed shortly afterwards. A liver biopsy revealed high grade lymphoma, an uncommon presentation for lymphoma. While malignancy is increased in dialysis patients, lymphoma is a relatively uncommon malignancy described. This case is a rare incidence of diffuse Non-Hodgkin's Lymphoma (NHL) isolated to the liver, causing fever, liver cell failure and death in a hemodialysis patient.

Entities:  

Mesh:

Year:  2007        PMID: 17899425     DOI: 10.1007/s11255-007-9285-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

1.  Two haemodialysis patients with unclear abdominal symptoms of similar origin.

Authors:  M A Norden; H Rabb
Journal:  Nephrol Dial Transplant       Date:  2001-12       Impact factor: 5.992

2.  A case of cutaneous Ki-1 positive anaplastic large cell lymphoma in a hemodialysed patient.

Authors:  N Kamada; T Kuwahara; A Hatamochi; H Shinkai
Journal:  J Dermatol       Date:  1998-03       Impact factor: 4.005

3.  Fever of unknown origin.

Authors:  R G Petersdorf
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

4.  Cancer and patients with end-stage renal failure.

Authors:  J R Curtis
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

5.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

Authors:  P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

6.  Serological evidence for reactivation of EBV infection due to uraemic immunodeficiency.

Authors:  B Winkelspecht; N Mueller-Lantzsch; H Köhler
Journal:  Nephrol Dial Transplant       Date:  1997-10       Impact factor: 5.992

7.  Fever of unknown origin in uremic patients: a controlled prospective study.

Authors:  M R Altiparmak; S Apaydin; R Ataman; F Tabak; A Mert; K Serdengecti; E Erek
Journal:  Scand J Infect Dis       Date:  2001

8.  [Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis].

Authors:  F Sano; M Koike; M Ishibashi; K Tuji; M Katoh; S Hasegawa; T Maeba; M Takahashi; S Ohwada; T Inoue; M Ishida
Journal:  Rinsho Ketsueki       Date:  1996-08

9.  Chemotherapy with cytosine arabinoside in a child with Burkitt's lymphoma on maintenance hemodialysis and hemofiltration.

Authors:  J M Pöschl; G Klaus; U Querfeld; R Ludwig; O Mehls
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

10.  Increased incidence of malignancy during chronic renal failure.

Authors:  A J Matas; R L Simmons; C M Kjellstrand; T J Buselmeier; J S Najarian
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.